【摘要】 目的 观察肝动脉插管栓塞治疗(TAE)序贯奥沙利铂、雷替曲塞联合安罗替尼治疗中晚期原发性肝癌(PLC)的效果及毒副反应。方法 选取2018年1月至2020年6月来自4个肿瘤中心的一线治疗后复发、进展的81例中晚期PLC患者，根据患者及家属意愿，其中40例接受TAE序贯安罗替尼联合奥沙利铂、雷替曲塞治疗。结果 40例患者客观缓解率(ORR)为35.0%,疾病控制率(DCR)为82.5%,中位总生存期(mOS)为18.2个月，中位无疾病进展期(mPFS)为8.6个月，1 a存活率(SR)为52.5%。Ⅰ～Ⅳ度毒副反应主要表现为消化道反应(40.0%)、骨髓抑制(67.5%)、肝毒性(27.5%)、周围神经毒性(25.0%)、高血压(22.5%)、声音嘶哑(35.0%)、皮肤反应(52.5%)和发热(20.0%),Ⅲ～Ⅳ度毒副反应分别为消化道反应(2.5%)、骨髓抑制(27.5%)、发热(2.5%),经积极处理均可缓解。结论 TAE序贯安罗替尼联合奥沙利铂、雷替曲塞治疗中晚期PLC安全有效，患者有临床获益，副反应可耐受，患者依从性良好。更多还原

【Abstract】 Objective To evaluate the efficacy and toxicity of the sequential therapy of transcatheterarterial embolization(TAE) and oxaliplatin, raltitrexed plus anlotinib in treating the patients with advanced primary liver cancer(PLC).Methods Eighty-one patients with advanced PLC admitted to 4 cancer center from January 2018 to June 2020 with recurrence or progression after first-line treatment were selected, according to the wishes of the patient or the family, 40 patients accepted the sequential therapy of TAE and raltitrexed, oxaliplatin plus anlotinib.Results The objective remission rate(ORR) of 40 patients was 35.0%, disease control rate(DCR) was 82.5%, median overall survival(mOS) was 18.2 months, median progression-free survival(mPFS) was 8.6 months, and one year survival rate(SR) was 52.5%. The main side effects(Ⅰ-Ⅳ) were digestive tract reaction(40.0%), myelosuppression(67.5%), hepatotoxicity(27.5%), peripheral neurotoxicity(25.0%), hypertension(22.5%), hoarseness(35.0%), skin reaction(52.5%) and fever(20.0%). The severe side effect(Ⅲ-Ⅳ) were digestive tract reaction(2.5%), myelosuppression(27.5%)and fever(2.5%). Most of these side effects can be remitted by the positive treatment.Conclusion The sequential therapy of TAE and oxaliplatin, raltitrexed plus anlotinib is safe and effective to the patients with advanced PLC.更多还原